628. Aggressive Lymphomas: Cellular Therapies: Poster I

A phase II multi institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Early administration of CD20 x CD3 bispecific antibodies 4 6 weeks after CAR T infusion for patients with residual or progressive large B cell lymphomas

Risk of second primary hematological malignancy post chimeric antigen receptor T cell therapy in diffuse large B cell lymphoma Propensity matched analysis using trinetx database

Bendamustine combined with fludarabine cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR T therapy for extranodal bulky R R B cell lymphoma

Characterizing differences in CAR T cell therapy outcomes based on sex in patients with large B cell lymphoma

Distinct inflammatory and immune recovery patterns after CD19 directed CAR T cell therapy in SLE and B cell lymphoma

Updated clinical outcomes of a Phase I II trial of bispecific CD19 CD20 targeted CAR T cells in patients with relapsed or refractory B cell non Hodgkin lymphoma

Early intervention for cytokine release syndrome after chimeric antigen receptor T cell therapy is associated with an increased risk of cytopenias and infections in patients with large B cell lymphoma

Icans mitigation in high risk elderly patients treated with CD28 co stimulatory anti CD19 CAR T cells using a standardization protocol – a pilot study

A simple 3 factor pre treatment score Toranomon Prognostic Score robustly stratifies progression risk in patients with relapsed refractory large B cell lymphoma receiving commercial CAR T cell therapy A real world analysis

CRE intestinal colonization correlates with increased progression risk following CAR T cell therapy in relapsed refractory lymphoma

Impact of prior B cell directed immunotherapy on the outcome of CD19 CAR T cell therapy in aggressive B cell lymphoma an analysis of the EBMT and the GoCART coalition

Real world outcomes with CAR T cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

Anti CD19 chimeric antigen receptor T cell therapy for patients with non Hodgkin s lymphoma and concurrent autoimmune disease

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein barr virus driven post transplant lymphoproliferative disease

Sequential CD19 CD22 CAR T cell therapy following ASCT shows improved efficacy versus CAR t alone in relapsed refractory large B cell lymphoma

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Correlation of T cell fitness of apheresis products with response to CAR T cell therapy in patients with relapsed or refractory large B cell lymphoma A prospective observational study at a single center

Timed PD 1 blockade synergizes with IL 7 CCL19 armoring to reverse CAR T exhaustion in PD L1 high large B cell lymphoma